NO308506B1 - Anvendelse av grønn porfyrin (Gp)-forbindelse for fremstilling av et fotokjemisk medikament - Google Patents

Anvendelse av grønn porfyrin (Gp)-forbindelse for fremstilling av et fotokjemisk medikament

Info

Publication number
NO308506B1
NO308506B1 NO944537A NO944537A NO308506B1 NO 308506 B1 NO308506 B1 NO 308506B1 NO 944537 A NO944537 A NO 944537A NO 944537 A NO944537 A NO 944537A NO 308506 B1 NO308506 B1 NO 308506B1
Authority
NO
Norway
Prior art keywords
photochemical
drug
compound
preparation
green porphyrin
Prior art date
Application number
NO944537A
Other languages
English (en)
Other versions
NO944537L (no
NO944537D0 (no
Inventor
Janice North
Original Assignee
Quadra Logic Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quadra Logic Tech Inc filed Critical Quadra Logic Tech Inc
Publication of NO944537D0 publication Critical patent/NO944537D0/no
Publication of NO944537L publication Critical patent/NO944537L/no
Publication of NO308506B1 publication Critical patent/NO308506B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
NO944537A 1992-05-27 1994-11-25 Anvendelse av grønn porfyrin (Gp)-forbindelse for fremstilling av et fotokjemisk medikament NO308506B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/889,707 US5776966A (en) 1992-05-27 1992-05-27 Selective cell inactivation in blood
PCT/CA1993/000215 WO1993024127A1 (en) 1992-05-27 1993-05-27 Selective cell inactivation in blood

Publications (3)

Publication Number Publication Date
NO944537D0 NO944537D0 (no) 1994-11-25
NO944537L NO944537L (no) 1995-01-20
NO308506B1 true NO308506B1 (no) 2000-09-25

Family

ID=25395640

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944537A NO308506B1 (no) 1992-05-27 1994-11-25 Anvendelse av grønn porfyrin (Gp)-forbindelse for fremstilling av et fotokjemisk medikament

Country Status (23)

Country Link
US (1) US5776966A (no)
EP (1) EP0642342B1 (no)
JP (1) JP3174821B2 (no)
KR (1) KR950701522A (no)
AT (1) ATE194491T1 (no)
AU (1) AU687734B2 (no)
CA (1) CA2136447C (no)
CZ (1) CZ283846B6 (no)
DE (1) DE69329026T2 (no)
DK (1) DK0642342T3 (no)
ES (1) ES2147754T3 (no)
FI (1) FI945586A (no)
GR (1) GR3034529T3 (no)
HU (1) HUT78021A (no)
IL (1) IL105815A (no)
MX (1) MX9303127A (no)
NO (1) NO308506B1 (no)
NZ (1) NZ252085A (no)
PT (1) PT642342E (no)
SK (1) SK143994A3 (no)
TW (1) TW257674B (no)
WO (1) WO1993024127A1 (no)
ZA (1) ZA933723B (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807881A (en) * 1992-05-27 1998-09-15 Quadra Logic Technologies, Inc. Method for selectively reducing activated leukocyte cell population
US5756541A (en) 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
CA2221912A1 (en) * 1997-11-21 1999-05-21 David Dolphin Photosensitizers with improved biodistribution and light-absorbing properties
US6117862A (en) 1998-10-09 2000-09-12 Qlt, Inc. Model and method for angiogenesis inhibition
US6602274B1 (en) 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
US7022843B1 (en) 1999-04-14 2006-04-04 The University Of British Columbia β,β′-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
US6734192B1 (en) * 1999-08-23 2004-05-11 Mp-1 Inc. Treatment of viral infections
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
WO2002064163A2 (en) 2001-02-15 2002-08-22 Qlt Inc. Reduction or prevention of pdt related inflammation
US7498029B2 (en) 2001-05-01 2009-03-03 The General Hospital Corporation Photoimmunotherapies for cancer using combination therapies
DE60219627T2 (de) * 2001-06-04 2008-02-07 The General Hospital Corp., Boston Nachweis und therapie von empfindlichem plaque mit photodynamischen verbindungen
US20040175373A1 (en) * 2002-06-28 2004-09-09 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
DK1539929T3 (da) * 2002-06-28 2013-07-15 Life Technologies Corp Fremgangsmåder til genoprettelse af immunrepertoiret i patienter med immunologiske defekter i forbindelse med autoimmunitet og transplantation af organer eller hæmatopoeitiske stamceller
US7220778B2 (en) * 2003-04-15 2007-05-22 The General Hospital Corporation Methods and devices for epithelial protection during photodynamic therapy
US7659301B2 (en) * 2003-04-15 2010-02-09 The General Hospital Corporation Methods and devices for epithelial protection during photodynamic therapy
KR100604350B1 (ko) 2004-07-15 2006-07-25 학교법인 인제학원 광역학 치료용 광민감성 물질로 유용한 사이클릭테트라피롤 고분자와 이의 제조방법
CA2724949A1 (en) * 2007-06-27 2008-12-31 The General Hospital Corporation Method and apparatus for optical inhibition of photodynamic therapy
US10328085B2 (en) 2014-05-09 2019-06-25 Uniwersytet Jagiellonski Cobalt porphyrins for the treatment of blood-related disorders
PL233504B1 (pl) 2014-05-09 2019-10-31 Univ Jagiellonski Protoporfiryna IX kobaltu do stosowania w leczeniu neutropenii i białaczek

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4610241A (en) * 1984-07-03 1986-09-09 Gordon Robert T Atherosclerosis treatment method
US5011684A (en) 1985-09-05 1991-04-30 Beth Israel Hospital Association Lysing or blocking unwanted cells with IL-2 receptor-specific binding substance
US5171749A (en) * 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
US5095030A (en) * 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
DE3821254A1 (de) 1988-06-23 1990-01-04 Hoffmann Elektrokohle Schleifstueck fuer stromabnehmer sowie verfahren zu seiner herstellung
US5190966A (en) * 1988-07-06 1993-03-02 Health Research, Inc. Purified hematoporphyrin dimers and trimers useful in photodynamic therapy
US5028594A (en) * 1988-12-27 1991-07-02 Naxcor Use of photodynamic compositions for cytotoxic effects
US4960408A (en) * 1989-01-10 1990-10-02 Klainer Albert S Treatment methods and vaccines for stimulating an immunological response against retroviruses
US5149708A (en) * 1989-06-07 1992-09-22 University Of British Columbia Photosensitizing Diels-Alder porphyrin derivatives
US5087636A (en) * 1990-02-20 1992-02-11 University Of British Columbia Method to destroy malignant cells in mononuclear cell populations
US5214036A (en) * 1990-03-08 1993-05-25 University Of British Columbia Benzoporphyrin derivatives for photodynamic therapy

Also Published As

Publication number Publication date
NO944537L (no) 1995-01-20
CA2136447C (en) 2001-06-19
AU4057193A (en) 1993-12-30
NO944537D0 (no) 1994-11-25
EP0642342A1 (en) 1995-03-15
CA2136447A1 (en) 1993-12-09
JP3174821B2 (ja) 2001-06-11
FI945586A (fi) 1995-01-27
ES2147754T3 (es) 2000-10-01
TW257674B (no) 1995-09-21
DK0642342T3 (da) 2000-10-09
DE69329026T2 (de) 2001-03-22
EP0642342B1 (en) 2000-07-12
GR3034529T3 (en) 2000-12-29
HU9403385D0 (en) 1995-02-28
SK143994A3 (en) 1996-07-03
US5776966A (en) 1998-07-07
NZ252085A (en) 1998-02-26
CZ283846B6 (cs) 1998-06-17
KR950701522A (ko) 1995-04-28
JPH08501278A (ja) 1996-02-13
WO1993024127A1 (en) 1993-12-09
IL105815A0 (en) 1993-09-22
MX9303127A (es) 1994-06-30
IL105815A (en) 2000-01-31
CZ291894A3 (en) 1995-09-13
ZA933723B (en) 1993-12-15
AU687734B2 (en) 1998-03-05
ATE194491T1 (de) 2000-07-15
HUT78021A (hu) 1999-05-28
PT642342E (pt) 2000-11-30
FI945586A0 (fi) 1994-11-28
DE69329026D1 (de) 2000-08-17

Similar Documents

Publication Publication Date Title
NO308506B1 (no) Anvendelse av grønn porfyrin (Gp)-forbindelse for fremstilling av et fotokjemisk medikament
ES2022886B3 (es) Conjunto de dispositivos luminosos para un sistema de tratamiento de pacientes por fotoactivacion.
ATE106740T1 (de) Herstellung von t-zellen und t-zellmembranen, verwendbar zur verhütung und behandlung von autoimmunkrankheiten.
AU6951087A (en) Pump block for interfacing irradiation chamber to photoactivation patient treatment system
IL126366A0 (en) Photopheresis treatment of leukocytes
ATE121952T1 (de) Krebsbehandlung.
ES8607916A1 (es) Un procedimiento para la preparacion de medicamentos influenciadores de la circulacion sanguinea, que contienen compuestos de bis (carboxamida)
ATE80616T1 (de) Prostaglandin e1-derivate und ihre therapeutische anwendung.
CA2270558A1 (en) Treatment of autoimmune diseases by photochemotherapy
ATE87826T1 (de) Herstellung und verwendung von purpurinen, chlorinen und purpurin und chlorin enthaltenden zubereitungen.
AU6950487A (en) Irradiation chamber for photoactivation patient treatment system
ATE78164T1 (de) Verwendung von metalloporphyrin zur umkehr des toxischen effekts der tumortherapie.
ES2169033T3 (es) Empleo de la manganeso-superoxidodismutasa (mn-sod) para la elaboracion de medicamentos para el tratamiento de enfermedades, en una dosis pequeña.
HUT42940A (en) Process for production of medical preparative
DE69113437T2 (de) Therapeutische Mittel für diabetisches Gangrän.
DE69724228D1 (de) Kombinationstherapie von topoisomerase ii toxinen und bis-dioxypiperazinderivaten
ES2011526A6 (es) Instalacion para la regeneracion y depouracion de la sangre.
Muller et al. THE EFFECT OF PORPHYRIN PHOTOSENSITIZERS ON THE TOXICITY OF l, 3‐BIS (2‐CHLOROETHYL)‐1‐NITROSOUREA IN C57BL/6J MICE
RU97103883A (ru) Способ усиления эффективности действия противоопухолевого химиопрепарата
RU94045639A (ru) Способ лечения инсулинозависимого сахарного диабета тяжелой формы течения
UA37041A (uk) Спосіб стимуляції функціональної активності т-лімфоцитів

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN NOVEMBER 2003